Answers are grounded in this paper and cite their sources.
Adult-onset Still's disease (AOSD) refractory to standard therapies remains a therapeutic challenge. Interleukin-1 signalling is independent of the Janus kinase (JAK) pathway, providing a rationale for combining anakinra with a JAK inhibitor (JAKi), although long-term clinical data are scarce. We describe a man diagnosed with AOSD at 28 years of age who presented with spiking fever, atypical flagellate rash, sore throat, polyarthritis, hepatosplenomegaly, serositis, neutrophilic leucocytosis, liver enzyme abnormalities, and a peak serum ferritin of 48,288 µg/L (glycosylated ferritin fraction ≤18%), fulfilling both Yamaguchi and Fautrel classification criteria. He also developed life-threatening myopericarditis with cardiac tamponade. Systemic manifestations responded to glucocorticoids and anakinra, but chronic polyarthritis developed that remained refractory over 18 months to anakinra, tocilizumab, etanercept, sarilumab, tofacitinib, and conventional immunosuppressants, with dependence on prednisone 15-20 mg/d. In September 2019, baricitinib was combined with anakinra, achieving low articular disease activity within weeks and allowing prednisone to be tapered to 5 mg/d. After secondary loss of articular response in May 2025, baricitinib was replaced by filgotinib while anakinra was maintained. At the last follow-up in August 2026, systemic manifestations remained controlled, with low articular disease activity and no serious or opportunistic infections, malignancy, venous thromboembolism, or major cardiovascular events during combination therapy. This case documents nearly 7 years of disease control and glucocorticoid sparing with dual targeted JAKi-anakinra therapy in multidrug-refractory AOSD, despite occasional articular flares and previous JAKi failure.
No takes yet. Share an insight, caveat, or question.
Narváez et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: